Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

• Status: Completed
• Trial end date: 2006-12-01

Summary

Recruiting in Germany only:

This study will evaluate the safety and efficacy of valsartan plus HCTZ in fixed dose combination in hypertensive patients not responding to treatment with the free combination of Candesartan plus HCTZ. In an optional extension patients with uncontrolled BP at the end of the core study can be treated with valsartan plus HCTZ in fixed dose combination plus amlodipine 5 mg for additional 4 weeks.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Angiotensin Receptor Antagonists; Candesartan; Candesartan cilexetil; Hydrochlorothiazide; Valsartan